Study links clot-buster, angioplasty combo with increased death risk

09/7/2005 | USA Today

Many heart attack patients are given a clot-busting drug prior to a planned angioplasty, but the combined treatment could increase a patient's risk of death following the artery-widening procedure, according to a new study. Researchers studying 1,667 patients found that 6% of patients given the clot-busting drug TNKase died within 30 days of their angioplasty, compared with just 3.8% of those who had an angioplasty with no clot-buster.

View Full Article in:

USA Today

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Chief Financial Officer
B. E. Smith
Miramar, FL
Claims Director
PacificSource
Springfield, OR
Consultant
Attest Health Care Advisors
Nationwide, SL_Nationwide
Biotechnology/Pharmaceutical Patent Attorney
Coats and Bennett PLLC
Cary, NC
Sr. Regulatory Specialist, Biotech Center of Expertise
BASF, The Chemical Co.
San Diego, CA